ZA200810790B - Stable laquinimod preparations - Google Patents

Stable laquinimod preparations

Info

Publication number
ZA200810790B
ZA200810790B ZA200810790A ZA200810790A ZA200810790B ZA 200810790 B ZA200810790 B ZA 200810790B ZA 200810790 A ZA200810790 A ZA 200810790A ZA 200810790 A ZA200810790 A ZA 200810790A ZA 200810790 B ZA200810790 B ZA 200810790B
Authority
ZA
South Africa
Prior art keywords
preparations
stable
stable laquinimod
laquinimod preparations
laquinimod
Prior art date
Application number
ZA200810790A
Other languages
English (en)
Inventor
Shulamit Patashnik
Daniella Licht
Adrian Gilbert
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of ZA200810790B publication Critical patent/ZA200810790B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
ZA200810790A 2006-06-12 2007-06-12 Stable laquinimod preparations ZA200810790B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81324706P 2006-06-12 2006-06-12

Publications (1)

Publication Number Publication Date
ZA200810790B true ZA200810790B (en) 2010-03-31

Family

ID=38832466

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810790A ZA200810790B (en) 2006-06-12 2007-06-12 Stable laquinimod preparations

Country Status (28)

Country Link
US (3) US7989473B2 (zh)
EP (1) EP2035001B1 (zh)
JP (1) JP5226678B2 (zh)
KR (4) KR20160013273A (zh)
CN (1) CN101466379B (zh)
AR (1) AR061348A1 (zh)
AT (1) ATE532515T1 (zh)
AU (1) AU2007258366B2 (zh)
BR (1) BRPI0713694A2 (zh)
CA (2) CA2899472C (zh)
CY (1) CY1113003T1 (zh)
DK (1) DK2035001T3 (zh)
EA (1) EA018031B1 (zh)
ES (1) ES2377149T3 (zh)
HK (1) HK1121971A1 (zh)
HR (1) HRP20120093T1 (zh)
IL (1) IL195724A (zh)
MX (1) MX2008015808A (zh)
NO (1) NO342485B1 (zh)
NZ (1) NZ573846A (zh)
PL (1) PL2035001T3 (zh)
PT (1) PT2035001E (zh)
RS (1) RS52169B (zh)
SI (1) SI2035001T1 (zh)
TW (1) TWI400073B (zh)
UA (1) UA96449C2 (zh)
WO (1) WO2007146248A2 (zh)
ZA (1) ZA200810790B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
UA92761C2 (ru) 2005-10-19 2010-12-10 Тева Фармасьютикл Индастриз, Лтд. Кристаллы лаквинимода натрия и способ их изготовления
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
EA021227B1 (ru) * 2008-09-03 2015-05-29 Тева Фармасьютикал Индастриз Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
ES2564931T3 (es) * 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
DK2467372T3 (en) * 2009-08-10 2016-08-22 Teva Pharma TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
PT2542079E (pt) * 2010-03-03 2014-07-18 Teva Pharma Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato
PE20130613A1 (es) * 2010-03-03 2013-06-23 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
SG183515A1 (en) * 2010-03-03 2012-10-30 Teva Pharma Treatment of lupus arthritis using laquinimod
US20120010239A1 (en) * 2010-07-09 2012-01-12 Ulf Tomas Fristedt 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
NZ611628A (en) * 2010-12-07 2015-06-26 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
PE20142319A1 (es) * 2011-07-28 2015-01-24 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
SG10201606204TA (en) * 2011-07-28 2016-09-29 Teva Pharma Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta
US8889627B2 (en) * 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
US9284276B2 (en) 2012-02-16 2016-03-15 Teva Pharmaceutical Industries, Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) * 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
US20130345257A1 (en) * 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410243A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) * 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
AU2014216199A1 (en) * 2013-02-15 2015-09-03 Teva Pharmaceutical Industries Ltd. Treatment of progressive forms of multiple sclerosis with laquinimod
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
EP2968203A1 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
JP2016533323A (ja) * 2013-09-27 2016-10-27 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症の治療のためのラキニモド併用療法
EP3082814A4 (en) * 2013-12-20 2017-06-21 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay huntington's disease progression
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
CN110193014B (zh) * 2019-06-06 2021-05-11 温州医科大学 一种注射用拉喹莫德胶束冻干制剂及制备方法、拉喹莫德注射制剂

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
EA005803B1 (ru) 1999-06-07 2005-06-30 Алтана Фарма Аг Новый препарат и форма для введения, включающие неустойчивое в кислой среде действующее вещество
US6395750B1 (en) 1999-10-25 2002-05-28 Active Biotech Ab Drugs for the treatment of malignant tumors
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
JP2002031610A (ja) 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20060188568A1 (en) 2003-10-30 2006-08-24 Lupin Limited Stable formulations of ace inhibitors and methods for preparation thereof
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
UA92761C2 (ru) 2005-10-19 2010-12-10 Тева Фармасьютикл Индастриз, Лтд. Кристаллы лаквинимода натрия и способ их изготовления
AU2007258366B2 (en) 2006-06-12 2012-10-25 Active Biotech, Ab Stable laquinimod preparations
US20080087929A1 (en) * 2006-10-11 2008-04-17 Infineon Technologies Ag Static random access memory with thin oxide capacitor
SI2234485T1 (sl) 2007-12-20 2014-03-31 Teva Pharmaceutical Industries Ltd. Stabilni lakvinimodni pripravki
EA021227B1 (ru) 2008-09-03 2015-05-29 Тева Фармасьютикал Индастриз Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
NZ597378A (en) 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
ES2564931T3 (es) 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
DK2467372T3 (en) 2009-08-10 2016-08-22 Teva Pharma TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD
PE20130613A1 (es) 2010-03-03 2013-06-23 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
PT2542079E (pt) 2010-03-03 2014-07-18 Teva Pharma Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato
SG183515A1 (en) 2010-03-03 2012-10-30 Teva Pharma Treatment of lupus arthritis using laquinimod
US20120010239A1 (en) 2010-07-09 2012-01-12 Ulf Tomas Fristedt 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도

Also Published As

Publication number Publication date
HK1121971A1 (en) 2009-05-08
TW200815006A (en) 2008-04-01
AR061348A1 (es) 2008-08-20
CN101466379B (zh) 2012-10-31
AU2007258366B2 (en) 2012-10-25
IL195724A (en) 2015-09-24
CA2654982C (en) 2015-11-10
KR101495327B1 (ko) 2015-02-24
EP2035001B1 (en) 2011-11-09
DK2035001T3 (da) 2012-02-27
US20120302600A1 (en) 2012-11-29
PT2035001E (pt) 2012-02-06
CY1113003T1 (el) 2016-04-13
WO2007146248A3 (en) 2008-12-24
EA200870599A1 (ru) 2009-06-30
SI2035001T1 (sl) 2012-03-30
NZ573846A (en) 2012-01-12
US20070293537A1 (en) 2007-12-20
NO342485B1 (no) 2018-05-28
US20110251235A1 (en) 2011-10-13
EA018031B1 (ru) 2013-05-30
RS52169B (en) 2012-08-31
IL195724A0 (en) 2009-09-01
US8383645B2 (en) 2013-02-26
UA96449C2 (en) 2011-11-10
US7989473B2 (en) 2011-08-02
CA2654982A1 (en) 2007-12-21
EP2035001A2 (en) 2009-03-18
PL2035001T3 (pl) 2012-05-31
AU2007258366A1 (en) 2007-12-21
JP2009539984A (ja) 2009-11-19
KR20150065951A (ko) 2015-06-15
TWI400073B (zh) 2013-07-01
HRP20120093T1 (hr) 2012-03-31
KR20140091778A (ko) 2014-07-22
MX2008015808A (es) 2009-02-17
ES2377149T3 (es) 2012-03-22
ATE532515T1 (de) 2011-11-15
NO20090175L (no) 2009-03-11
CN101466379A (zh) 2009-06-24
CA2899472A1 (en) 2007-12-21
KR20160013273A (ko) 2016-02-03
EP2035001A4 (en) 2009-09-23
CA2899472C (en) 2019-04-30
JP5226678B2 (ja) 2013-07-03
KR20090017694A (ko) 2009-02-18
BRPI0713694A2 (pt) 2012-10-30
WO2007146248A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
HK1220126A1 (zh) 穩定的拉喹莫德製劑
ZA200810790B (en) Stable laquinimod preparations
IL193265A0 (en) Quinoline derivatives
GB2435419B (en) Formulations
EP1988922A4 (en) PROTEIN FORMULATIONS
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
EP2016080A4 (en) DIHYDROPYRAZOLOPYRIMIDINONDERIVATE
HK1134284A1 (en) Pyridizinone derivatives pyridizinone
EP1973405A4 (en) HYDROXYALKYMARYLAMIDE DERIVATIVES
HK1124233A1 (en) Quinoline derivatives as antibacterical agents
HK1137344A1 (en) Tape preparation
GB0605780D0 (en) Formulations
GB0618697D0 (en) Formulations
HK1136276A1 (zh) -羥基甲基-噁唑烷- -酮衍生物
IL193211A0 (en) Indazole-heteroaryl derivatives
GB0610336D0 (en) Formulations
EP2043633A4 (en) THIADIAZOLIDINONDERIVATE
GB0610140D0 (en) Protein stability
GB0718346D0 (en) Tooth-bleaching preparations
ZA200807460B (en) Spiroindolinone derivatives
GB0625671D0 (en) Protein formulation
GB0718404D0 (en) Formulations
ZA200806877B (en) Quinoline Derivatives
AU4913P (en) KencoralGL Kennedia coccinea
GB0616155D0 (en) Food preparations